<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> and usually arises from colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Screening and removal of <z:mpath ids='MPATH_491'>polyps</z:mpath> reduce mortality from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath> are known to aggregate in families; however the genetic determinants for risk of <z:mpath ids='MPATH_491'>polyps</z:mpath> are unknown </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, it has been shown that <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drug</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) use decreases the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and the incidence and size of <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we used data from the Tennessee Colorectal <z:mpath ids='MPATH_491'>Polyp</z:mpath> Study and the Tennessee-Indiana <z:mpath ids='MPATH_270'>Adenoma</z:mpath> Recurrence Study to evaluate selected genes from the <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> (PG) metabolism and signaling pathways for association with risk of <z:mpath ids='MPATH_491'>polyps</z:mpath> and for interactions with <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Our design consisted of discovery and replication phases for a total of 2,551 Caucasian <z:mpath ids='MPATH_491'>polyp</z:mpath> cases and 3,285 Caucasian controls </plain></SENT>
<SENT sid="6" pm="."><plain>We carried out multivariable logistic regression to test for association in both the discovery and replication phase and further examined the results with meta-analysis </plain></SENT>
<SENT sid="7" pm="."><plain>We detected association signals in the genes <z:chebi fb="0" ids="26338">PGE</z:chebi> receptor 3 (PTGER3) and 15-hydroxyprostaglandin dehydrogenase (HPGD), both strong biologic candidates for influence on <z:mpath ids='MPATH_491'>polyp</z:mpath> risk </plain></SENT>
<SENT sid="8" pm="."><plain>We did not observe the previously reported effects and effect modification in PG-endoperoxide synthase 2 (PTGS2), <z:chebi fb="0" ids="26338">PGE</z:chebi> receptor 2 (PTGER2), or <z:chebi fb="0" ids="26338">PGE</z:chebi> receptor 4 (PTGER4), although we did observe a single nucleotide polymorphism in PTGER2 associated with risk of multiple <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>We also observed effect modification of the HPGD signal by <z:chebi fb="1" ids="35475">NSAID</z:chebi> exposure </plain></SENT>
</text></document>